- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05933369
The Impact of Clinical Pharmacist Intervention on Asthmatic Patient's Outcomes
The Impact of Clinical Pharmacist Intervention on Asthmatic Patient's Outcomes at the University of Gondar Comprehensive and Specialized Hospital, Northwest Ethiopia, 2022: A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There are poor patient outcomes in the study area as it is evident in previous studies where almost ninety five percent of patients had not well controlled Asthma. Moreover, the rate of non-adherence to inhalational anti asthmatics is high and more than half of asthmatic patients received inappropriate treatment. All those poor patient outcomes can be easily prevented and those studies have recommended that patient education and proper patient consultation to optimize the benefits of treatment by integrating clinical pharmacists. Thus, pharmacists are at sealing point at which most of medication information must be provided if a conducive system is created which can greatly improve patient's treatment outcome.
This study will generate strong evidence on the impact of clinical pharmacists at improving asthma control. It will also be an excellent tool in ascertaining and promoting what a well-trained clinical pharmacist can contribute to the health care through patient centered practice. Currently, there are a great number of clinical pharmacists who are wasting their knowledge and skill in a routine and traditional way of dispensing despite they are well trained to provide a patient centered care which in turn curb many limitations of a traditional way of dispensing with a minimal patient contact time and provision of in adequate information to them.
Despite the importance of clinical pharmacists services to the improvement of asthma outcomes, clinical pharmacists face many challenges in the involvement of asthma patients, such as poor awareness among general public, lack of specific legislation and recognition from other health care providers Previously done studies have shown that clinical pharmacist led interventions had improvements in asthma outcomes. However, evidence for different interventions is not totally conclusive; Therefore, the present randomized controlled trial will set up to study the hypothesis that such pharmacist intervention will result in an improved asthma control in adult patients over a 6-month period.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Eden A Mehari, Msc
- Phone Number: +251988214167
- Email: edenabetu@gmail.com
Study Locations
-
-
-
Gondar, Ethiopia
- Recruiting
- University of Gondar Specialized and Comprehensive Hospital
-
Contact:
- Eden A Mehari, Msc
- Phone Number: +251988214167
- Email: edenabetu@gmail.com
-
Contact:
- Abrham W Dagne, PhD
- Email: leabrham@gmail.com
-
Principal Investigator:
- Eden A Mehari, Msc &MPH
-
Sub-Investigator:
- Abrham W Dagne, PhD
-
Sub-Investigator:
- Esileman A Muche, Msc
-
Sub-Investigator:
- Sewnet A Kebede, MPH
-
Sub-Investigator:
- Gebrehiwot L Legese, MD
-
Sub-Investigator:
- Faisel D Sema, Msc
-
Sub-Investigator:
- Gizework A Mekonnen, Msc
-
Sub-Investigator:
- Rahel B Abebe, Msc
-
Sub-Investigator:
- Abebech T Gelaye, Msc
-
Sub-Investigator:
- Leila K Kemal, Msc
-
Sub-Investigator:
- Abdulwase M Seid, Msc
-
Sub-Investigator:
- Abdisa G Jara, Msc
-
Sub-Investigator:
- Abiyot E Gurmu, Msc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age of 18 years or older
- Physician's diagnosis of asthma
Exclusion Criteria:
- Participation in another asthma education program
- Pregnancy
- Communication difficulties
- Seasonal asthma (asthma symptoms that only occur in a seasonal pattern)
- Other pathologies such as COPD, emphysema, lung cancer, respiratory infection
- Terminal illness (any disease that is reasonably expected to result in the patient's death)
- Having an asthma control test level of <15 (indicating seriously uncontrolled asthma; for ethical reasons, these patients will be immediately referred ) or
- Having an asthma control test level equaling 25 (indicating complete asthma control; no room for improvement) will be excluded from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Patients in the intervention group will receive a protocol-defined clinical pharmacist intervention at the start of the study and at the 1- , 3 and 6-month follow-up visits.
|
Patients in the intervention group will receive a protocol-defined intervention at the start of the study and at the 1- , 3 and 6-month follow-up visits for education on disease and treatment 40 minutes, administration and dosage 6 minutes, drug interaction and other drug therapy problems 20 minutes for a total of 66 minutes.
The intervention will include education about asthma triggers and the need of minimizing them, asthma symptoms, warning signs, proper inhalation use technique, cigarette smoking cession when appropriate, the need of adherence and they will also counseled to wash their mouth after the use of controller medications.
In addition, pharmaceutical care evaluation will be carried out and any drug therapy problems will be addressed accordingly and finally every intervention provided will be recorded.
|
No Intervention: Control
Patients in the control group will receive the usual pharmacist care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the level of asthma control
Time Frame: change in asthma control at 1,3 and 6 month
|
A blinded investigator will assess change in asthma control using the Asthma control test score (ACT).
This is a clinically validated asthma control measure that consists of five questions with five alternative responses (classified by decreasing level of asthma control, scored from 5 to 1).
The ACT score (range 5-25) is calculated by adding the responses to the five questions; the higher the score, the better asthma control.
The ACT will be completed at randomization, as well as 1, 3, and 6 months later.
Patients with a maximum score of 25 will be considered "completely controlled," while those with an ACT score of 20-24 will be considered as having "well-managed" asthma, and those with a score of 15-19 will be categorized as "uncontrolled" asthma.
|
change in asthma control at 1,3 and 6 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of exacerbations of asthma
Time Frame: 6 month
|
Asthma exacerbation is one that necessitates the use of oral glucocorticoids, as well as a trip to the emergency room or hospitalization
|
6 month
|
Improvement in Adherence level
Time Frame: 6 month
|
Two validated measures of adherence will be used to assess adherence throughout the study: prescription refill rates and self reporting.
During the trial period, the number of units of controller medicine provided to each patient will be documented, and adherence will be computed.
The test of adherence to inhaler instrument (TAI) will be used to assess self reported adherence at the end of the trial (TAI).)
The TAI is a reliable and homogeneous questionnaire to identify easily non-adherence and to classify from a clinical perspective the barriers related to the use of inhalers in asthma TAI scores 50, 46-49 and less than 45 will be considered as adherent, intermediate adherent and non-adherent respectively.
|
6 month
|
Change in Inhalation technique skill
Time Frame: 6 month
|
The inhalation technique will be rated using an eight-point checklist for metered dosage inhalers (MDI).
One point will be awarded for each correct step, and the total score for the inhalation technique will be given as a percentage of correct steps.
Patients who make serious inhalation technique errors (failure to remove cap and/or shake MDI; failure to load device and/or inhale fast and deeply via device ) will be given a sum score of zero.
For ethical reasons, such major errors will also be corrected in patients belonging to the control group.
Good MDIs use technique: when patients respond to greater than or equal to seven the mean score of MDIs use technique (≥70%).
Poor MDIs use technique: when patients respond to less than seven the mean score of MDIs use technique (< 70%).
|
6 month
|
change in Knowledge about disease and treatment
Time Frame: 6 month
|
An updated version of the Knowledge of Asthma and Asthma Medicine questionnaire will be used to assess patients' knowledge of asthma and its treatment at the start of the intervention period and after the 6-month follow-up.
|
6 month
|
Number of Drug therapy problems reduced
Time Frame: 6 month
|
Using the PCNE(Pharmaceutical Care Network Europe) Classification tool Version 6.2 from Pharmaceutical Care Network Europe (PCNE) drug therapy problems will be identified.
The PCNE V 6.2 has four primary issue domains, eight primary cause domains, and five primary intervention domains.
There are 37 grouped sub-domains for causes, 9 grouped sub-domains for problems, and 17 grouped sub-domains for effects.Pharmaceutical care evaluation will be carried out and any drug therapy problems will be addressed accordingly.
|
6 month
|
Change in Asthma Quality of life
Time Frame: 6 month
|
Asthma-specific quality of life will be assessed at the start of the intervention period and after the 6-month follow-up period using the Standardized Asthma Quality of Life Questionnaire (AQLQ(S)).
|
6 month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eden A Mehari, Msc, University of Gondar
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ASTHMA-PHAR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on Clincal pharmacist intervention
-
The Leeds Teaching Hospitals NHS TrustCompleted
-
Zahava Rosenberg-YungerCompletedUncontrolled Asthma
-
Nova Southeastern UniversityBaptist Health South FloridaWithdrawnHeart Failure
-
Hospital Comarcal de IncaCompletedElderly (People Aged 65 or More) | Polypharmacy (People Under Treatment With 5 or More Drugs)Spain
-
Shin Kong Wu Ho-Su Memorial HospitalUnknownChronic Disease | ElderlyTaiwan
-
Northeast Iowa Medical Education FoundationCompletedTorsades de Pointes | Qt Interval, Variation in | Torsades de Pointe Caused by Drug (Disorder)United States
-
Consorci Sanitari del MaresmeCompleted
-
University of North CarolinaNational Institutes of Health (NIH); Purdue University; Indiana University School... and other collaboratorsCompleted
-
University of North CarolinaNational Institutes of Health (NIH); Indiana University School of Medicine; Wishard...Completed
-
Aalborg UniversityResearch Unit for General Practice at Aalborg University; The Quality Unit... and other collaboratorsRecruitingPolypharmacy Patients | Pharmacist InterventionDenmark